These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Oncogenic K-ras activates p38 to maintain colorectal cancer cell proliferation during MEK inhibition.
    Author: van Houdt WJ, de Bruijn MT, Emmink BL, Raats D, Hoogwater FJ, Borel Rinkes IH, Kranenburg O.
    Journal: Cell Oncol; 2010 Jan 01; 32(4):245-57. PubMed ID: 20413844.
    Abstract:
    BACKGROUND: Colon carcinomas frequently contain activating mutations in the K-ras proto-oncogene. K-ras itself is a poor drug target and drug development efforts have mostly focused on components of the classical Ras-activated MEK/ERK pathway. Here we have studied whether endogenous oncogenic K-ras affects the dependency of colorectal tumor cells on MEK/ERK signaling. METHODS: K-ras mutant colorectal tumor cell lines C26, HCT116 and L169 were used. K-ras or components of the MEK/ERK and p38 pathway were suppressed by RNA interference (RNAi). MEK was inhibited by U0126. p38 was inhibited by SB203850. RESULTS: MEK inhibition, or suppression of MEK1/2 or ERK1/2 by RNA interference, reduced the proliferation rate of all colorectal cancer cell lines. However, cell proliferation returned to normal after two weeks of chronic inhibition, despite the continued suppression of MEK or ERK. In contrast, K-ras-suppressed tumor cells entered an irreversible senescent-like state following ERK pathway inhibition. MEK inhibition or ERK1/2 suppression caused activation of p38alpha in a K-ras-dependent manner. Inhibition or suppression of p38alpha prevented the recovery of K-ras mutant tumor cells during prolonged MEK inhibition. CONCLUSION: Oncogenic K-ras activates p38alpha to maintain cell proliferation during MEK inhibition. MEK-targeting therapeutics can create an acquired tumor cell dependency on p38alpha.
    [Abstract] [Full Text] [Related] [New Search]